Jazz Pharmaceuticals(JAZZ) - 2025 Q1 - Quarterly Results

"In the first quarter of 2025, our focus on commercial execution resulted in total revenues of $898 million, led by the strong performance of Xywav and Epidiolex. In addition, our team continues to receive positive feedback from healthcare providers on the launch of Ziihera in its first approved indication of 2L HER2+ BTC. We are affirming our 2025 total revenue guidance range of$4.15 - $4.40 billion, reflecting our confidence in our commercial portfolio delivering top-line growth this year," said Bruce Co ...